Veteran actress Nafisa Ali Sodhi is courageously undergoing chemotherapy for a recurrence of stage 4 peritoneal cancer, after an initial misdiagnosis ...

Results from the phase 2 (dose optimization) part of the REJOICE-Ovarian01 phase 2/3 trial showed that raludotatug deruxtecan (R-DXd) demonstrated clinically meaningful response rates in patients with ...

Chemotherapy drugs are administered via a port system in the abdominal cavity. The MHH is one of the first clinics in Germany to establish this method.

The European Society for Medical Oncology "Living Guideline" for Gastric Cancer suggests that narrow-band imaging or ...

Nafisa Ali Sodhi has resumed chemotherapy for peritoneal cancer, which had advanced to stage 4. She was diagnosed with stage 3 peritoneal cancer in 2018.

Circulating tumor DNA (ctDNA)—genetic material shed from tumors into the bloodstream—may help risk-stratify patients with ...

Rare cancer diagnoses can lead to isolation due to limited information and support, making self-advocacy crucial. Finding the ...

In Breast Cancer Awareness Month, Breast Cancer Now’s Catherine Priestley and Katie Peduto, highlight the signs and symptoms ...

Due to a lack of robust evidence, the benefits and risks of adding chemotherapy directly into the abdominal cavity (intraperitoneal chemotherapy, or IPC) for stomach cancer are unclear.

BERLIN -- After multiple failed attempts, an immune checkpoint inhibitor has broken through and landed a significant overall ...

R-DXd showed a 50.5% objective response rate in platinum-resistant ovarian cancer, with a 5.6 mg/kg dose deemed optimal for further study. The safety profile was manageable, with 93.5% experiencing ...

When pembrolizumab was added to paclitaxel with or without bevacizumab in platinum-resistant ovarian cancer, significant ...